TheraKine

Research on eye diseases such as Diabetic Retinopathy, Age Related Macular Edema, and Uveitis has proven the effectiveness of treatment with biologic compounds. At present, frequent skin, intravenous or intraviteal injections are required. In systemic use, the dose can be very high, and frequent treatment is necessary. Costs are often in excess of $60,000/year.
This high cost was one factor driving TheraKine’s approach, another was the current delay in treatment due to the need for referral to a rheumatologist to use most biologics. Current treatment modalities will literally bankrupt the heath care system if applied to all who would benefit from them. Treatment of AMD alone could exceed $34 billion dollars annually. An eye implant that slowly releases the exact amount of compound needed would significantly reduce the cost and complexity of treating these disorders. In addition it will reduce the complications associated with biologics that are systemically delivered and the risks associated with multiple injections into the eye.

Therakine is also developing a topical version of our product will reduce complications and improve the outcomes of refractive surgery (LASIK, LASEK, PRK, and epi-LASIK) and decrease scarring in corneal injury or infection. This multibillion dollar market is drive by increased demand for perfect outcomes. Our product is designed to decrease the poor outcomes associated with the vagaries of corneal wound healing. We expect that it would be used prophylactically in all procedures.







Research on eye diseases such as Diabetic Retinopathy, Age Related Macular Edema, and Uveitis has proven the effectiveness of treatment with biologic compounds. At present, frequent skin, intravenous or intraviteal injections are required. In systemic use, the dose can be very high, and frequent treatment is necessary. Costs are often in excess of $60,000/year. This high cost was one factor driving TheraKine’s approach, another was the current delay in treatment due to the need for referral to a rheumatologist to use most biologics. Current treatment modalities will literally bankrupt the heath care system if applied to all who would benefit from them. Treatment of AMD alone could exceed $34 billion dollars annually. An eye implant that slowly releases the exact amount of compound needed would significantly reduce the cost and complexity of treating these disorders. In addition it will reduce the complications associated with biologics that are systemically delivered and the risks associated with multiple injections into the eye. Therakine is also developing a topical version of our product will reduce complications and improve the outcomes of refractive surgery (LASIK, LASEK, PRK, and epi-LASIK) and decrease scarring in corneal injury or infection. This multibillion dollar market is drive by increased demand for perfect outcomes. Our product is designed to decrease the poor outcomes associated with the vagaries of corneal wound healing. We expect that it would be used prophylactically in all procedures.